Trial Profile
Neoadjuvant Treatment of Prostate Cancer With Bicalutamide and Raloxifene Prior to Radical Prostatectomy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Raloxifene (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 17 Jan 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.
- 12 May 2017 New trial record